Document Detail


Impact of spiramycin treatment and gestational age on maturation of Toxoplasma gondii immunoglobulin G avidity in pregnant women.
MedLine Citation:
PMID:  17202303     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The objective of the present study was to investigate the maturation of immunoglobulin G (IgG) avidity after Toxoplasma gondii seroconversion during pregnancy and the factors that affect IgG avidity over time. The study used 309 serum samples from 117 women and a multiple linear mixed regression analysis to show the patterns of variation of IgG avidity throughout gestation. The IgG avidity ratios and the patterns of their evolution with time were quite diverse among the women and were statistically heterogeneous (P = 0.011); however, the trend was toward a statistically significant increase (P < 0.0001). On average, a 1.0167-fold increase was observed for each additional gestational week after the putative date of infection. At 12 weeks after putative infection (the expected IgG avidity maturation time), the mean avidity ratio was 16.6% (95% confidence interval, 15.4 to 17.9%). At all times, the avidity ratio remained significantly heterogeneous among the women (P < 0.05); for 95% of them, that ratio ranged from 7.8 to 35.3% at 12 weeks after putative infection. Maternal age at the putative time of infection did not influence the maturation of IgG avidity. However, on average, a 1.009-fold decrease (P = 0.03) in that avidity was observed for each additional week of gestational age before infection and a 1.03-fold increase (P = 0.0003) was observed for each additional week of delay to the onset of spiramycin treatment. The rate of increase in the avidity ratio was lower if infection occurred late in pregnancy and higher if the delay to treatment was long. This information cannot allow accurate determination of the delay since the time of infection. The present results provide support for interpretation of the assay and caution against overinterpretation.
Authors:
M Lefevre-Pettazzoni; A Bissery; M Wallon; G Cozon; F Peyron; M Rabilloud
Related Documents :
21743843 - The impact of preeclampsia on gene expression at the maternal-fetal interface.
22382643 - Clinical outcomes of elective single morula embryo transfer versus elective single blas...
3391333 - Eisenmenger's syndrome and pregnancy.
Publication Detail:
Type:  Journal Article     Date:  2007-01-03
Journal Detail:
Title:  Clinical and vaccine immunology : CVI     Volume:  14     ISSN:  1556-6811     ISO Abbreviation:  Clin. Vaccine Immunol.     Publication Date:  2007 Mar 
Date Detail:
Created Date:  2007-03-07     Completed Date:  2007-09-25     Revised Date:  2013-06-06    
Medline Journal Info:
Nlm Unique ID:  101252125     Medline TA:  Clin Vaccine Immunol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  239-43     Citation Subset:  IM    
Affiliation:
Hospices Civils de Lyon, Service de Biostatistique, 162 avenue Lacassagne, F-69424 Lyon Cedex 03, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antibodies, Protozoan / immunology*
Antibody Affinity*
Coccidiostats / therapeutic use*
Female
Gestational Age
Humans
Immunoglobulin G / immunology*
Pregnancy
Pregnancy Complications, Parasitic / drug therapy*,  immunology
Retrospective Studies
Spiramycin / therapeutic use*
Toxoplasma / immunology*
Toxoplasmosis / drug therapy*,  immunology
Chemical
Reg. No./Substance:
0/Antibodies, Protozoan; 0/Coccidiostats; 0/Immunoglobulin G; 8025-81-8/Spiramycin
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Expression profiling and lung cancer development.
Next Document:  Effects of a diphtheria-tetanus-acellular pertussis vaccine on immune responses in murine local lymp...